NCT04464889 - HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation | Biotech Hunter

Timeline

Start Date

July 2, 2020

Primary Completion Date

July 31, 2023

Study Completion Date

July 31, 2025

Conditions

Acute Myeloid LeukemiaAcute Lymphoid LeukemiaMyelodysplastic SyndromesMyeloproliferative DisordersChronic Myeloid LeukemiaMyelofibrosisMultiple MyelomaMalignant Lymphoma

Interventions

DRUG

MDG1021 dose 1

3 patients to receive dose1: target dose of 0.3x10\^6 HA-1H TCR transduced T cells/kg BW ±20% in 100 mL

DRUG

MDG1021 dose 2

3 patients to receive dose 2: target dose of 1x10\^6 HA-1H TCR transduced T cells/kg BW ±20% in 100 mL

DRUG

MDG1021 dose 3

3 patients to receive dose 3: target dose of 3x10\^6 HA-1H TCR transduced T cells/kg BW +20% in 100 mL

DRUG

MDG1021 optimal dose

20 patients to receive the selected optimal dose

Trial Locations (1)

2333 ZA Leiden

Leiden University Medical Centre, Leiden